X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DISHMAN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DISHMAN PHARMA BIOCON /
DISHMAN PHARMA
 
P/E (TTM) x 17.6 25.1 70.3% View Chart
P/BV x 2.8 3.3 83.2% View Chart
Dividend Yield % 0.4 0.7 62.6%  

Financials

 BIOCON    DISHMAN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
DISHMAN PHARMA
Mar-16
BIOCON /
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188374 317.3%   
Low Rs305129 236.6%   
Sales per share (Unadj.) Rs68.7197.8 34.7%  
Earnings per share (Unadj.) Rs7.621.2 35.6%  
Cash flow per share (Unadj.) Rs14.034.7 40.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.8 16.9%  
Book value per share (Unadj.) Rs86.3179.9 48.0%  
Shares outstanding (eoy) m600.0080.69 743.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.91.3 853.8%   
Avg P/E ratio x98.911.9 833.0%  
P/CF ratio (eoy) x53.47.2 737.3%  
Price / Book Value ratio x8.61.4 618.0%  
Dividend payout %13.29.4 140.4%   
Avg Mkt Cap Rs m447,90020,306 2,205.8%   
No. of employees `0006.10.8 741.7%   
Total wages/salary Rs m9,3115,355 173.9%   
Avg. sales/employee Rs Th6,705.819,252.7 34.8%   
Avg. wages/employee Rs Th1,514.26,459.5 23.4%   
Avg. net profit/employee Rs Th736.92,064.1 35.7%   
INCOME DATA
Net Sales Rs m41,23415,961 258.4%  
Other income Rs m2,062265 776.9%   
Total revenues Rs m43,29616,226 266.8%   
Gross profit Rs m8,2914,103 202.1%  
Depreciation Rs m3,8511,091 353.1%   
Interest Rs m615944 65.1%   
Profit before tax Rs m5,8872,334 252.3%   
Minority Interest Rs m2130-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569624 251.6%   
Profit after tax Rs m4,5311,711 264.8%  
Gross profit margin %20.125.7 78.2%  
Effective tax rate %26.726.7 99.7%   
Net profit margin %11.010.7 102.5%  
BALANCE SHEET DATA
Current assets Rs m41,48611,018 376.5%   
Current liabilities Rs m21,4139,517 225.0%   
Net working cap to sales %48.79.4 517.7%  
Current ratio x1.91.2 167.3%  
Inventory Days Days64110 57.9%  
Debtors Days Days9435 270.3%  
Net fixed assets Rs m50,66116,304 310.7%   
Share capital Rs m3,000161 1,858.7%   
"Free" reserves Rs m48,80812,907 378.2%   
Net worth Rs m51,80814,516 356.9%   
Long term debt Rs m17,8984,189 427.2%   
Total assets Rs m99,89729,805 335.2%  
Interest coverage x10.63.5 304.6%   
Debt to equity ratio x0.30.3 119.7%  
Sales to assets ratio x0.40.5 77.1%   
Return on assets %5.28.9 57.8%  
Return on equity %8.711.8 74.2%  
Return on capital %9.617.5 55.0%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m12,0584,952 243.5%   
Fx outflow Rs m7,348697 1,054.5%   
Net fx Rs m4,7104,255 110.7%   
CASH FLOW
From Operations Rs m6,6212,786 237.6%  
From Investments Rs m-6,840-1,529 447.4%  
From Financial Activity Rs m-2,397-941 254.7%  
Net Cashflow Rs m-2,612316 -825.5%  

Share Holding

Indian Promoters % 40.4 61.4 65.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.7 227.0%  
FIIs % 10.7 12.7 84.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 22.1 90.0%  
Shareholders   109,995 46,261 237.8%  
Pledged promoter(s) holding % 0.0 35.8 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 19, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS